This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study sample
The use of power calculations to determine the sample size were not reported. The participants were identified from those who had access to the three study locations in each corresponding time period. Screening was offered to 199 of the 1,262 individuals in the NEC setting, to 172 of the 267 in the CFH group, and to 45 of the 1,311 in the GP group. The characteristics of the individuals in the samples were not provided.
Study design
This was a comparative study of screening in three different types of location. At each type of location, eligible individuals were offered screening. The study was carried out at the NEC of the Homerton Hospital, in a large GP with academic affiliation, and in several CFH (three hostels, an emergency accommodation centre and a drop-in centre). It was unclear how the individuals were subsequently followed after screening.
Analysis of effectiveness
It appears that the analysis of the effectiveness has been limited to those individuals with complete data. The primary health outcomes were the numbers of TB cases identified, tuberculin reactors requiring chemoprophylaxis and BCG vaccinations. The study groups were not compared at baseline.
Effectiveness results
Three TB cases were identified in the NEC versus 0 in the other settings.
There were 5 tuberculin reactors requiring chemoprophylaxis (which was then completed) in the NEC group, 6 in the CFH group, and 2 in the GP group.
There were 18 BCG vaccinations in the NEC group, 27 in the CFH group, and 14 in the GP group.
Clinical conclusions
The results of the effectiveness analysis were unclear since no cases of TB were identified in the GP and CFH settings.
Measure of benefits used in the economic analysis
Although the authors estimated the cost per case of TB prevented, it appears that a true cost-effectiveness analysis has not been performed and the number of TB cases prevented was used only in the cost analysis. Thus, no summary benefit measure was used in the economic evaluation. Hence, in effect, a cost-consequences analysis was conducted.
Direct costs
Discounting was not relevant since the costs of the screening programme were likely to have been incurred in less than two years. The unit costs were provided separately from the quantities of resources used. The health services included in the economic evaluation referred to nursing and clerical costs, treatment costs (e.g. investigations, inpatient stay, outpatient visits, drugs), overheads, contact tracing for those found positive, and chemoprophylaxis. The cost/resource boundary adopted in the analysis was not explicitly stated, but it appears to have been that of the NHS. The resource use data were estimated on the basis of a series of assumptions, some of which were derived from the literature. The source of the cost data was not reported and neither was the price year. The costs were standardised as the cost per case of TB prevented in order to compare the estimated costs in the three different settings. This calculation assumed that each case of TB would result in an average of 4.5 further cases, 3 of which developed early.
